We have rooms available in Horton Halls, our university-managed housing facility. Learn more and apply now.
Learn more about our key research areas and our research objectives.
We are building a positive research culture at St George's where researchers feel empowered to do their best work and develop their career.
We're putting £5.8 million of Office for Students funding towards improving facilities and equipment for our students.
City St George’s welcomed researchers, industry partners and local government partners across the London healthcare sector to celebrate the launch of the Health Innovation Nexus
Your gift to St George’s will inspire our students, our research, and our community, and ultimately impact the patients who will benefit from the care and expertise of our graduates around the world.
Enjoy stories of impact and support from generous donations.
To ensure that new discoveries deliver patient benefits, we work with industry partners through commercial partnerships, industry-sponsored research and university spin-out companies. We have expertise in navigating regulatory pathways, particularly the introduction of new areas of technology and in clinical trials.
We have a number of highly-productive relationships with small and large companies, particularly in the areas of diagnostic development, vaccines, and clinical trials.
The institute has an impressive record of generating spin-out companies, creating commercial development opportunities for our research, ranging from fundamental scientific discoveries to close-to-clinic applications.
Professor Sanjeev Krishna and Dr Henry Staines are working with Newcastle-based industrial partners - QuantuMDx- to implement new technologies that use cheap, rapid and disposal cartridges for point-of-care diagnostics of HPV.
Professor Philip Butcher and his team are working with the UK Biotech company QuantuMDx Ltd to develop much needed novel technologies for improving the diagnosis of tuberculosis (TB).
Dr Jason Hinds and BμG@S Bioscience are harnessing the power of microbial genomics to assess the impact of international vaccine roll-out initiatives.
Dr Tim Bull and Dr Kai Hilpert are developing a novel method to stimulate growth of mycobacteria, with important implications for human and veterinary medicine.
Professor Anthony Coates and Dr Yanmin Hu have adopted an innovative approach to rejuvenate antibiotics rendered ineffective by resistance.
Browser does not support script.